重症肌无力(Myasthenia Gravis， MG)是一种在神经肌肉兴奋传递过程中发生障碍而导致的疾病。根据发病机理的不同可以分为乙酰胆碱受体型和非乙酰胆碱受体型。目前对重症肌无力的治疗方法主要有抗乙酰胆碱脂酶剂、肾上腺皮质激素、胸腺切除术、血浆置换、免疫抑制疗法和γ-球蛋白疗法等，除此之外多肽疫苗的使用也正在研制当中。
重症肌无力是一种主要累及神经肌肉接头突触后膜乙酰胆碱受体,由乙酰胆碱受体(AchR)抗体介导的、细胞免疫依赖性、补体参与的自身免疫性疾病1。重症肌无力是一种常见病多发病，发病率约10/10万左右（美国）2。

重症肌无力的发病机理的研究
乙酰胆碱受体型
非乙酰胆碱受体型
重症肌无力的治疗

1． Im SH, Barchan D, Maiti PK, et al. Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4. J. Immunol, 2001, 166: 6893-6898
2． Armstrong,-S-M; Schumann,-L Myasthenia gravis: diagnosis and treatment. J-Am-Acad-Nurse-Pract. 2003 Feb; 15(2): 72-78.
3． Fambrough DM, Drachman DB, Satyamurti S. Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors [J]. Science, 1973,182: 293-295.
4． Chistadoss P, Poussin M, Deng C. Animal models of myasthenia gravis. Clin Immunol, 2000,94: 75-87.
5． Vincent,-A; Beeson,-D; Lang,-B Molecular targets for autoimmune and genetic disorders of neuromuscular transmission. Eur-J-Biochem. 2000 Dec; 267(23): 6717-6728.
6． Sasakura,-Y; Kumasaka,-S; Takahashi,-T; Shindo,-J Myasthenia gravis associated with reduced masticatory function. Int-J-Oral-Maxillofac-Surg. 2000 Oct; 29(5): 381-384.
7． Engel,-A-G; Ohno,-K; Sine,-S-M Congenital myasthenic syndromes: recent advances. Arch-Neurol. 1999 Feb; 56(2): 163-167.
8． Lindstrom,-J-M Acetylcholine receptors and myasthenia. Muscle-Nerve. 2000 Apr; 23(4): 453-477.
9． Hara H, Hayashi K, Ohta K, et al. Nicotinic acetycholine receptor mRNA in myasthenic thymuses: association with in trathymic pathogenesis of myasthenia gravis[J]. Biochemical and Biophy Res Communication, 1993, 194(3): 1267-1275.
10． Vincent,-A; Bowen,-J; Newsom-Davis,-J; McConville,-J Seronegative generalised myasthenia gra vis: clinical features, antibodies, and their targets. Lancet-Neurol. 2003 Feb; 2(2): 99-106
11． Skeie,-G-O; Lunde,-P-K; Sejersted,-O-M; Mygland,-A; Aarli,-J-A; Gilhus,-N-E Autoimmunity against the ryanodine receptor in myasthenia gravis. Acta-Physiol-Scand. 2001 Mar; 171(3): 379-384.
12． Maruyama K, Matsubara S, Natori R, et al. Connectin, an elastic protein of muscle. Characterization and Function. J Biochem, 1977,82: 317-337.
13． Lu CZ, Link H, Mo XA, et al. Anti-presynaptic membrane receptor antibodies in myasthenia gravis. J Neurol Sci, 1991, 102: 39-45.
14． Pascuzzi,-R-M The edrophonium test. Semin-Neurol. 2003 Mar; 23(1): 83-88.
15． Bedlack,-R-S; Sanders,-D-B Steroid treatment for myasthenia gravis: steroids have an important role. Muscle-Nerve. 2002 Jan; 25(1): 117-121.
16． Evoli,-A; Batocchi,-A-P; Minisci,-C; Di-Schino,-C; Tonali,-P Therapeutic options in ocular myasthenia gravis. Neuromuscul-Disord. 2001 Mar; 11(2): 208-216.
17． Abel,-M; Eisenkraft,-J-B Anesth..